Vistagen Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Vistagen Therapeutics

13/02/2024 23:32

* Vistagen Therapeutics Inc  VTGN.OQ  reported a quarterly
adjusted loss of 22 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of $-1.50.  The mean expectation of
four analysts for the quarter was for a loss of 30 cents per
share. Wall Street expected results to range from -39 cents
to -27 cents per share.
    * Revenue rose 128.6% to $411.40 thousand from a year ago;
analysts expected $544.50 thousand. 
    * Vistagen Therapeutics Inc's reported EPS for the quarter
was a
loss of 22 cents​.
    * The company reported a quarterly loss of $6.35 million.
    * Vistagen Therapeutics Inc shares had risen by 0.2% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 8.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Vistagen
Therapeutics Inc is $12.00 
This summary was machine generated from LSEG data February 13 at
11:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.30          -0.22          Beat
 Sep. 30 2023      -0.68          -0.66          Beat
 Mar. 31 2023      -1.50          -1.75          Missed